Share Prices & Company Research

Market News

22 Mar 2019 | 07:54

Nuformix starts clinical study for chemotherapy-induced nausea treatment

Nuformix, which uses cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, said it had commenced clinical studies for its lead asset.

The asset, NXP001, was in development as a treatment for chemotherapy-induced nausea and vomiting.

First dosing took place on 20 March in a cross-over study that aimed to measure the relative bioavailability of NXP001 compared to Merck's EMEND in healthy subjects.

Dosing would complete during April 2019 with results expected by end of the first half of 2019.

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.